Christian Zwicky Rejecting opportunities. Last year, we received as many as 20 inquiries per week regarding testing for COVID-19. This shows how much potential our solution offers. But as a startup, it’s very important for a decision to correspond to our own strategy in order avoid losing focus.
Zwicky We’ve developed a digital platform based on artificial intelligence for molecular breath analysis. The aim is to use this non-invasive procedure in the future to diagnose illnesses early on, or to be able to forecast the efficacy of medications for each individual patient.
Zwicky With studies and scientific publications that show that our technology works. For example, we demonstrated in the areas of epilepsy and sleep apnea that we can analyze medication concentrations and specific biomarkers in real time in patients’ exhaled breath.
Zwicky Because our validated studies are most advanced in these areas, and we want to implement them in routine clinical practice as quickly as possible. As a startup, we are very pragmatic and focused, and we know that our solution will eventually enable a much wider area of application, such as diagnosing lung diseases or early cancer detection.
Zwicky By concentrating on our priorities and repeating the following like a mantra: “This is our strategy. This is what we want to do. We will continue doing so.” Because we’d need additional resources for everything else
Number of employees: 6
Founded in: 2018
Area of activity: Molecular breath analysis in the medtech sector
Noteworthy: The advanced artificial intelligence of the digital platform has significant potential for a broad range of applications in research as well as for personalized medicine.